循環器ジャーナル69巻4号

2021年10月発行

特集 プレシジョン・メディシン時代における腫瘍循環器学の重要性 Ⅲ章　プレシジョン・メディシン時代における循環器系の予防・診断・治療技術

腫瘍循環器領域における不整脈

著者： 庄司正昭¹

所属機関： ¹国立がん研究センター中央病院総合内科・循環器内科

ページ範囲：P.600 - P.609

Point
・がんの治療によって様々な不整脈が惹起されうるが，致死的不整脈には特に注意する．
・不整脈治療方針決定には腫瘍医と循環器医は協議し診療を進めていくことが肝要である．
・がん治療を完遂するために，がん専門施設と総合病院の連携の重要性を認識したい．

参考文献

1) Hu YF, Liu CJ, Chang PM, et al:Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients. Int J Cardiol 165:355-357, 2013

2) Conen D, Wong JA, Sandhu RK, et al:Risk of Malignant Cancer Among Women With New-Onset Atrial Fibrillation. JAMA Cardiol 1:389-396, 2016

3) Kattelus H, Kesäniemi YA, Huikuri H, et al:Cancer increases the risk of atrial fibrillation during long-term follow-up（OPERA study）. PLoS One 13:e0205454, 2018

4) Farmakis D, Parissis J, Filippatos G:Insights into onco-cardiology:atrial fibrillation in cancer. J Am Coll Cardiol 63:945-953, 2014

5) Tamargo J, Caballero R, Delpón E:Cancer chemotherapy and cardiac arrhythmias:a review. Drug Saf 38:129-152, 2015

6) Moriyama S, Yokoyama T, Irie K, et al:Atrial fibrillation observed in a patient with esophageal cancer treated with fluorouracil. J Cardiol Cases 20:183-186, 2019

7) Guglin M, Aljayeh M, Saiyad S, et al:Introducing a new entity:chemotherapy-induced arrhythmia. Europace 11:1579-1586, 2009

8) Yang X, Li X, Yuan M, et al:Anticancer Therapy-Induced Atrial Fibrillation:Electrophysiology and Related Mechanisms. Front Pharmacol 9:1058, 2018

9) Kilickap S, Barista I, Akgul E, et al:Early and late arrhythmogenic effects of doxorubicin. South Med J 100:262-265, 2007

）in chemotherapy pretreated non-small cell lung cancer patients:a pilot trial. Lung Cancer 35:59-64, 2002

11) Yuan M, Tse G, Zhang Z, et al:The incidence of atrial fibrillation with trastuzumab treatment:A systematic review and meta-analysis. Cardiovasc Ther 36:e12475, 2018

12) Chu TF, Rupnick MA, Kerkela R, et al:Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019, 2007

13) Mego M, Reckova M, Obertova J, et al:Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol 18:1906-1907, 2007

14) Wang ML, Rule S, Martin P, et al:Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507-516, 2012

15) Byrd JC, Brown JR, O'Brien S, et al:Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371:213-223, 2014

16) Siegel JP, Puri RK:Interleukin-2 toxicity. J Clin Oncol 9:694-704, 1991

17) Alvi RM, Frigault MJ, Fradley MG, et al:Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells（CAR-T）. J Am Coll Cardiol 74:3099-3108, 2019

18) Tonorezos ES, Stillwell EE, Calloway JJ, et al:Arrhythmias in the setting of hematopoietic cell transplants. Bone Marrow Transplant 50:1212-1216, 2015

19) Vaporciyan AA, Correa AM, Rice DC, et al:Risk factors associated with atrial fibrillation after non cardiac thoracic surgery:analysis of 2588 patients. J Thorac Cardiovasc Surg 127:779-786, 2004

20) Chin JH, Moon YJ, Jo JY, et al:Association between postoperatively developed atrial fibrillation and long-term mortality after esophagectomy in esophageal cancer patients:an observantional study. PLoS One 11:e0154931, 2016 doi:10.1371.

21) Apte N, Dherange P, Mustafa U, et al:Cancer Radiation Therapy May Be Associated With Atrial Fibrillation. Front Cardiovasc Med 8:610915, 2021

22) Barlogie B, Tricot G, Anaissie E, et al:Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354:1021-1030, 2006

23) Johnson DB, Balko JM, Compton ML, et al:Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med 375:1749-1755, 2016

24) Naing A, Veasey-Rodrigues H, Hong DS, et al:Electrocardiograms（ECGs）in phase 1 abtucabcer dryg development:the MD Anderson Cancer Center experience with 8518 ECGs. Ann Oncol 23:2960-2963, 2012

25) Weinberg SL:The electrocardiogram in acute arsenic poisoning. Am Heart J 60:971-975, 1960

26) Pickham D, Helfenbein E, Shinn JA, et al:How many patients need QT interval monitoring in critical care units? Preliminary report of the QT in Practice study. J Electrocardiol 43:572-576, 2010

27) Zelster D, Justo D, Halkin A, et al:Torsade de pointes due to noncardiac drugs:most patients have easily identifiable risk factors. Medicine 82:282-290, 2003

28) Ruiz-Garcia A, Houk BE, Pithavala YK, et al:Effect of axitinib on the QT interval in healthy volunteers. Cancer Chemother Pharmacol 75:619-628, 2015